How Mobocertinib inhibits EGFR exon 20 to treat disease

Mobocertinib is a targeted anti-cancer drug mainly used to treat non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Its mechanism of action is different from other epidermal growth factor receptor (EGFR) inhibitors. It specifically targets EGFR exon 20 insertion mutations and can effectively inhibit the proliferation and spread of cancer cells. The following is the mechanism of action and therapeutic effect of mobosetinib:

1. TargetingEGFR exon 20 mutation:

EGFR is an important receptor on the cell surface. It participates in the occurrence and development of tumors by promoting cell division and proliferation. EGFR exon 20 insertion mutations can lead to abnormal activation of the EGFR receptor, and this mutation is a driver of various cancers such as non-small cell lung cancer. Mobosetinib irreversibly binds to EGFR exon 20 mutations, inhibiting its kinase activity and preventing tumor cell proliferation and migration. Unlike other EGFR inhibitors, mobosertinib can specifically act on this type of mutation and has higher therapeutic targeting and effectiveness.

2. Anti-tumor activity:

In cell culture models, mobosetinib was able to inhibit cell proliferation driven by different EGFR exon 20 insertion mutations at lower concentrations than wild-typeEGFR signal. In animal xenograft tumor models, mobosetinib showed significant anti-tumor activity against tumors driven by EGFR exon 20 mutations and could effectively inhibit tumor growth.

3. Clinical effects:

Clinical studies have shown that mobosetinib has significant efficacy in the treatmentEGFR exon 20 insertion mutation non-small cell lung cancer. After patients took moboxetinib, tumor growth was effectively inhibited, and some patients even achieved complete remission.

Keyword tags: Mobocertinib, Mobocertinib, EGFR mutation, non-small cell lung cancer, EGFR exon 20, targeted therapy, anti-tumor drugs, inhibition of EGFR, cell proliferation, metabolites

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib